Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of OncoTherapy Science, Inc.. A complete text table follows the diagram.
Precision-medicine services supplied 99% of revenue as gene analysis expanded and drug discovery remained a long-cycle investment.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Cancer Precision Medical Business | 1 | 430M | 99.5% of reported total |
| Research & development of pharmaceutical products | 1 | 2.3M | 0.5% of reported total |
| Revenues From External Customers | 2 | 432M | Reported six-month total · ¥432M |
| Operating loss | 2 | 476M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 908M | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Cancer Precision Medical Business | Revenues From External Customers | 430M |
| Research & development of pharmaceutical products | Revenues From External Customers | 2.3M |
| Revenues From External Customers | Operating costs & expenses | 432M |
| Operating loss | Operating costs & expenses | 476M |